Probiotic Modulation of Immune Response Mechanisms

Obtaining and amplifying a patient's lung microbiome for personalized medicine applications like prognosis, antibiotic testing, and transplantation. The method involves culturing bronchoalveolar lavage samples in specific media to expand the lung bacteria populations.

Source

An antiviral probiotic that can effectively prevent and treat viral infections. The probiotic contains strains of Lactobacillus bacteria that have been selected for their ability to enhance expression of antiviral factors and reduce expression of factors that inhibit antiviral activity. The strains also have 16S rRNA gene sequences similar to the selected strains. Administering these probiotic strains can boost the body's natural antiviral defenses and provide protection against viral infections, including combined viral and bacterial infections.

Source

Compositions and formulations containing live microbial populations isolated from plants that can be used to treat and/or prevent immune system disorders, and conditions related to inflammation. The compositions can be in the form of pharmaceutical compositions, medical foods, dietary supplements, or solid food stuffs. The formulations can contain specific plant-derived bacterial and fungal species that can reduce inflammation when ingested.

Source

Recombinant microbes with reduced colonization properties for use as therapeutic delivery vehicles. The microbes have reduced expression/activity of proteins involved in adhesion to host tissues. This reduces the risk of the therapeutic microbes colonizing the body after delivery and causing unintended effects. The modification involves reducing sortase, fibronectin-binding proteins, autolysins, surface-layer proteins, and other factors that promote adherence.

Source

A composition for treating and preventing viral infections like COVID-19. The composition contains extracts of a bacterial strain called Lactobacillus fermentum Qi6 grown in biofilm form. The extracts inhibit viral entry and spread by modulating the immune system and potentially binding to viral receptors. The extracts also have potential antiviral proteins.

Source

A bacterial composition that can be used as a pharmaceutical, adjuvant, or food ingredient to induce proliferation of T helper 17 (Th17) cells in the gut. The composition comprises certain species of human-derived bacteria or their culture supernatants that have been shown to strongly induce Th17 cells. These bacteria can be isolated from fecal samples and cultured. Administering the bacterial composition can promote immune function and help prevent or treat diseases that benefit from a Th17 response, such as infectious diseases.

Source

Combination therapy for respiratory infections that uses immunomodulatory agents and binding agents like antibodies. The combination involves administering an agent that can bind to the infectious pathogen, like an antibody, along with an immunomodulatory agent like a probiotic. The binding agent targets and neutralizes the pathogen, while the immunomodulatory agent enhances the immune response against it. Administering the binding agent by inhalation targets the respiratory infection.

Source

Detecting exposure of a patient to an infectious pathogen and treating the patient via analysis and classification of the patient's microbiome. The method involves detecting exposure to a pathogen, analyzing the patient's microbiome to identify opportunistic pathogens indicating disease onset/recovery, and treating the patient with a customized therapeutic composition based on the microbiome analysis.

Source

Oral compositions containing lactoferrin, probiotic bacteria, and other ingredients for treating respiratory viral infections like COVID-19. The compositions can include lactoferrin derivatives, Lactobacillus paracasei bacteria, N-acetylcysteine, and hyaluronic acid. The lactoferrin and bacteria boost antiviral immunity and inhibit virus replication.

Source

Using Bifidobacterium animalis to treat and prevent avian influenza virus infections. The Bifidobacterium animalis probiotic enhances survival and reduces lung pathology when given orally to mice infected with H7N9 avian influenza.

Source

Prophylactic or therapeutic treatment of lower respiratory tract (LRT) viral infections, particularly coronaviruses, using BLIS-producing Streptococcus salivarius strains and extracts thereof. The BLIS product inhibits the growth of LRT viruses, including SARS-CoV-2, and can be used to prevent or treat LRT virus infections. The treatment involves administering an effective amount of the BLIS product like S. salivarius strain Glasgow3.

Source

Recombinant bacteria that produce D-lactate and/or L-lactate in vivo for treating autoimmune and inflammatory diseases. The bacteria are engineered to contain inducible lactate production genes that are activated in the low-oxygen gut environment. Administering the engineered bacteria to patients increases lactate levels, which then reduce inflammation and treat diseases like multiple sclerosis and colitis.

Source

Composition containing a combination of lactic acid bacteria and fermented milk that promotes the production of interleukin-10 (IL-10) while inhibiting production of interleukin-12 (IL-12). The composition has improved ability to promote anti-inflammatory IL-10 production compared to using lactic acid bacteria or fermented milk alone.

Source

Leveraging glycosidases and sulfatases produced by bacteria to degrade host glycans and inhibit viral infections. The bacteria Bacteroides thetaiotaomicron and Bacteroides ovatus, common members of the human gut microbiota, can degrade heparan sulfate (HS), a host glycan essential for viral entry. The abundance of B. thetaiotaomicron and B. ovatus decreased in COVID-19 patients, suggesting a potential link between microbiome composition and SARS-CoV-2 infectivity. Administering HS-degrading enzymes or bacteria to degrade HS on host cells could reduce viral binding and infection.

Source

A probiotic combination containing specific strains of Lactobacillus and Bifidobacterium bacteria to modulate the immune system and reduce the risk of infections in adults and elderly, especially seasonal infections like flu. The combination includes Lactobacillus plantarum and Bifidobacterium lactis along with other strains of Lactobacillus and Bifidobacterium.

Source

Evaluating and reducing mosquito-attractiveness of an individual. It involves collecting a skin sample, sequencing the skin microbiome, analyzing the microbial composition, normalizing the data, and using a classifier to compute a mosquito attractiveness score. The score compares to a threshold to categorize as highly or poorly attractive. If highly attractive, skin microbe interventions are administered to reduce attractiveness.

Source

Using an E. coli strain expressing high levels of the sugar molecule alpha-Galactose (alpha-Gal) as a feed additive, probiotic or oral vaccine to prevent or reduce infectious diseases in animals caused by pathogens that express alpha-Gal on their surface. The E. coli strain is used in non-human animals, like fish and poultry, that do not naturally produce alpha-Gal. Administering the alpha-Gal-rich E. coli strain stimulates an immune response to alpha-Gal, which then provides cross-protection against pathogens expressing alpha-Gal.

Source

Engineered bacteria, such as Lactobacillus, as a vaccine platform to express immunogenic viral peptides to induce an immune response against pathogenic organisms like coronaviruses. The recombinant bacteria are safe, well tolerated, and augment the immune response to achieve a therapeutic effect. The vaccine platform targets protease cleavage sites in viral spike proteins to prevent cleavage and reduce infectivity. It aims to induce mucosal IgA responses via oral delivery to prevent viral entry at mucosal surfaces, along with systemic immunity. This vaccine approach using genetically engineered bacteria provides an adaptable and accessible mucosal vaccination strategy that can be rapidly deployed against emerging pathogens like coronaviruses.

Source

Composition containing vesicles derived from Lactobacillus paracasei to prevent, treat or alleviate viral infectious diseases and respiratory diseases. The vesicles can be administered orally, inhaled or topically via food, drugs, cosmetics to deliver the active ingredient to the lungs and respiratory system.

Source

Enteric-coated granular composition containing purified bee venom melittin and lactic acid bacteria for oral administration to enhance the immune system and recover from kidney injury. The composition contains melittin derived from bee venom and lactic acid bacteria like Lactobacillus. The melittin is purified to contain 60-65% melittin. The enteric coating allows release in the intestine. It enhances the immune system by increasing cytotoxic T cells, helper T cells, and B cells, and recovering from kidney injury by reducing inflammatory cytokines and NGAL protein expression.

Source